π¬ Novartis halts CAR-T trials after serious side effects
Novartis has stopped its autoimmune CAR-T trials following three reported deaths. This development occurred at the clinical trial sites under investigation. The halt was announced after the incidents were recorded around late 2023. Meanwhile, BMS has also decided to pause its own related studies for review. Future steps will involve a comprehensive safety reassessment by regulatory bodies. π¬